Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting

Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets...

Full description

Saved in:
Bibliographic Details
Main Authors: E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
Format: Article
Language:Russian
Published: IRBIS LLC 2021-07-01
Series:Фармакоэкономика
Subjects:
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/522
Tags: Add Tag
No Tags, Be the first to tag this record!